Work

A phase 3 trial of fixed dose combinations of fianlimab (anti–LAG-3) + cemiplimab (anti–PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma.

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.16_suppl.tps9611

Authors: Nikhil I. Khushalani, Jayakumar Mani, Jocelyn Booth, Zoe Zhang, Mark Salvati, Israel Lowy, Matthew G. Fury, Karl Lewis, Garen Manvelian, Hussein A. Tawbi

Institutions: Moffitt Cancer Center, Regeneron (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Regeneron Pharmaceuticals

OpenAlex ID: W4399570412

Cites:

Cited by: 2

Related to: 10